{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:07:33Z","timestamp":1784092053228,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Acute lymphoblastic leukemia (ALL) is a malignant hematological disease that accounts for approximately 20% of adult leukemia. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently recognized as one of potentially curative treatments for ALL. Though pretransplant consolidation chemotherapy is generally considered essential, there is limited research on the optimal number of consolidation cycles, which leaves the ideal timing for transplant unclear. In this study, we retrospectively analyzed the clinical outcomes of 40 adult patients diagnosed with Philadelphia chromosome-negative ALL (Ph-negative ALL) who underwent allo-HSCT at our center between January 2014 and May 2025. Among these patients, eighteen received a single cycle of consolidation chemotherapy prior to transplant, while 22 underwent multiple cycles. No statistically significant differences were observed between the single and multiple consolidation groups in terms of overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR), or non-relapse mortality (NRM). The single consolidation group demonstrated 3-year OS rates of 57%, compared to 56% in the multiple consolidation group (p = 0.83). For DFS, the single consolidation group showed 3-year rates of 51%, versus 52% in the multiple group (p = 0.97). Regarding CIR, the single consolidation group had 3-year rates of 18%, compared to 28% in the multiple group (p = 0.48). In terms of NRM, the single consolidation group exhibited 3-year rates of 25%, versus 20% in the multiple group (p = 0.45). Our real-world findings indicate that a single cycle of pretransplant consolidation chemotherapy yields comparable clinical outcomes compared to multiple cycles. These results provide valuable evidence for potentially shortening the overall treatment duration for adult patients with Ph-negative ALL and may assist clinicians in determining the optimal timing for transplant.<\/jats:p>","DOI":"10.3389\/fonc.2026.1795501","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:42:20Z","timestamp":1784090540000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of pretransplant consolidation chemotherapy on clinical outcomes in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a single-center retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiayi","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Hematology, the Second Hospital of Dalian Medical University","place":["Dalian, China"]},{"name":"Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Second Hospital of Dalian Medical University","place":["Dalian, China"]},{"name":"Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Second Hospital of Dalian Medical University","place":["Dalian, China"]},{"name":"Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Second Hospital of Dalian Medical University","place":["Dalian, China"]},{"name":"Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Second Hospital of Dalian Medical University","place":["Dalian, China"]},{"name":"Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Ninth People\u2019s Hospital Affiliated to Shanghai Jiaotong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Second Hospital of Dalian Medical University","place":["Dalian, China"]},{"name":"Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01236-y","article-title":"Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed\/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy","volume":"35","author":"Hu","year":"2021","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-409813","article-title":"Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11912-018-0679-9","article-title":"Hematopoietic stem cell transplantation for adult Philadelphia-negative acute lymphoblastic leukemia in the first complete remission in the era of minimal residual disease","volume":"20","author":"Bourlon","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26281","article-title":"Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed\/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study","volume":"96","author":"Jabbour","year":"2021","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029611","article-title":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial","volume":"147","author":"Boissel","year":"2026","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2017.05.015","article-title":"Hematopoietic cell transplantation for acute lymphoblastic leukemia in adult patients","volume":"10","author":"El Fakih","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bjh.16616","article-title":"At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII\/ECOG E2993 trial","volume":"191","author":"Ganzel","year":"2020","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404420","article-title":"Allogeneic stem cell transplantation improves the outcome of adults with t(1,19)\/E2A-PBX1 and t(4;11)\/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study","volume":"20","author":"Vey","year":"2006","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01738-3","article-title":"Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients","volume":"37","author":"Boyiadzis","year":"2023","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.009","article-title":"Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.4743","article-title":"High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial","volume":"31","author":"Schaich","year":"2013","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"326.e1","DOI":"10.1016\/j.jtct.2022.03.017","article-title":"Allogeneic hematopoietic stem cell transplantation for adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in second complete remission","volume":"28","author":"Kaito","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12704","article-title":"Haploidentical hematopoietic stem cell transplantation for paediatric high-risk T-cell acute lymphoblastic leukaemia","volume":"20","author":"Xu","year":"2016","journal-title":"Pediatr Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02560-3","article-title":"Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given","volume":"39","author":"Rodr\u00edguez-Arbol\u00ed","year":"2025","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02178.x","article-title":"No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"110","author":"Cahn","year":"2000","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1254","article-title":"Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission","volume":"96","author":"Tallman","year":"2000","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28498","article-title":"Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"120","author":"Yeshurun","year":"2014","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1845340","article-title":"Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission","volume":"62","author":"Fu","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.784","article-title":"Pretransplant consolidation is not beneficial for adults with ALL undergoing myeloablative allogeneic transplantation","volume":"24","author":"Bejanyan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.clml.2022.02.007","article-title":"Pretransplant consolidation therapies improve the outcome of myeloablative allogeneic transplantation in adults with Ph-negative acute lymphoblastic leukemia","volume":"22","author":"Ozdemir","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3324\/haematol.2024.286350","article-title":"Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation","volume":"110","author":"Algeri","year":"2025","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.17.7428","article-title":"Late congestive heart failure after hematopoietic cell transplantation","volume":"26","author":"Armenian","year":"2008","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.09.013","article-title":"National Cancer Institute-National Heart, Lung and Blood Institute\/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction","volume":"17","author":"Nieder","year":"2011","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1795501\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:42:39Z","timestamp":1784090559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1795501\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1795501"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1795501","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1795501"}}